EA
CRL icon

Ellsworth Advisors’s Charles River Laboratories CRL Stock Holding History

Ellsworth Advisors’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-20,570
Closed -$3.8M – 177
2024
Q4 		$3.8M Sell
20,570
-218
-1% -$42K 1% 45
2024
Q3 		$4.09M Buy
+20,788
New +$4.32M 1.06% 45

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IC
Impactive Capital New York City, New York $1.4B AUM 13.97% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Ellsworth Advisors's CRL Position: Q1 2025 in Review

Ellsworth Advisors sold out of Charles River Laboratories (CRL) in Q1 2025, closing a stake of 20,570 shares — an estimated $3.8M sold.

Ellsworth Advisors first reported a position in CRL in Q3 2024 and held it in 2 quarters. The position peaked at $4.09M in Q3 2024. 561 funds tracked by Wall St. Rank hold CRL as of Q1 2025.

  • Ellsworth Advisors reported no remaining Charles River Laboratories position as of Q1 2025 after selling out during the quarter.
  • Ellsworth Advisors sold 20,570 Charles River Laboratories shares in Q1 2025, an estimated $3.8M.
  • Ellsworth Advisors first reported a position in Charles River Laboratories in Q3 2024 and held it in 2 quarters.
  • Ellsworth Advisors's Charles River Laboratories position peaked at $4.09M in Q3 2024.
  • 561 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2025.

Based on Ellsworth Advisors's 13F filing for Q1 2025, filed 28 May 2025.